Langerhans cell histiocytosis: intrinsic immunoediting properties

KŘENOVÁ, Zdenka, Eliška TVRDÍKOVÁ, Jaroslav ŠTĚRBA, Daniela KODYTKOVÁ and Leoš KŘEN. Langerhans cell histiocytosis: intrinsic immunoediting properties. In XXV. Konference dětských hematologů a onkologů České a Slovenské republiky. 2015. ISBN 978-80-210-7958-8.

Basic information

Original name

Langerhans cell histiocytosis: intrinsic immunoediting properties

Authors

KŘENOVÁ, Zdenka (203 Czech Republic, guarantor, belonging to the institution), Eliška TVRDÍKOVÁ (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution), Daniela KODYTKOVÁ (203 Czech Republic, belonging to the institution) and Leoš KŘEN (203 Czech Republic, belonging to the institution)

Edition

XXV. Konference dětských hematologů a onkologů České a Slovenské republiky, 2015

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/15:00085104

Organization unit

Faculty of Medicine

ISBN

978-80-210-7958-8

Keywords in English

langerhans cell histiocytosis; non-classical immunomodulatory molecules; intrinsic immunoediting properties

Tags

EL OK

---

Abstract

V originále

Non-classical HLA-molecules physiologically protect the fetus from maternal allorecognition, this mechanism seems to be used by some tumors during their development. PD-L1 is physiologically expressed mainly on antigen presenting cells, some types of tumors use this ligand to supress host immune reactions. The expression of non-classical immunomodulatory molecules (HLA-G, HLA-E, HLA-F) as well as the expression of immune checkpoint regulator programmed death ligand (PD-L1) is not characterized in Langerhans cell histiocytosis (LCH). Our data suggest that non-classical immunomodulatory molecules and immune checkpoint molecules may play role in immunoediting process during development of LCH. Further studies regarding immunoediting properties including non-classical HLA molecules and immune checkpoints ligands appear warranted for better understanding and therapy of this enigmatic disorder.